Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STYLE 1 dupilumab for pruritus of lichen simplex chronicus
2024-514737-37-00Phase 3Completed
- Sponsor
- Sanofi
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in neurodermatitis comparing Dupilumab with Matched placebo (2 arms). Primary endpoint: WI-NRS responder rate at Week 24. Started Mar 2025; status: completed.
02
Drugs
03
Conditions
neurodermatitis
Beyond the preview
Go deeper on 2024-514737-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514737-37-00.